Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.

Salvador-Martín S, García-González X, García MI, Blanco C, García-Alfonso P, Robles L, Grávalos C, Pachón V, Longo F, Martínez V, Sanjurjo-Sáez M, López-Fernández LA.

Pharmacol Res. 2018 Sep 11;136:133-139. doi: 10.1016/j.phrs.2018.08.026. [Epub ahead of print]

PMID:
30213564
2.

Robotic dispensing improves patient safety, inventory management, and staff satisfaction in an outpatient hospital pharmacy.

Rodriguez-Gonzalez CG, Herranz-Alonso A, Escudero-Vilaplana V, Ais-Larisgoitia MA, Iglesias-Peinado I, Sanjurjo-Saez M.

J Eval Clin Pract. 2018 Aug 22. doi: 10.1111/jep.13014. [Epub ahead of print]

PMID:
30136339
3.

Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.

Revuelta-Herrero JL, Giménez-Manzorro A, Matilla-Peña A, Herranz-Alonso A, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2018 Jun 28. doi: 10.1111/jcpt.12727. [Epub ahead of print]

PMID:
29956354
4.

Drug cost avoidance in clinical trials of breast cancer.

Mañes-Sevilla M, Romero-Jiménez R, Herranz-Alonso A, Sánchez-Fresneda M, Gonzalez-Haba E, Collado-Borrel R, Benedi-González J, Sanjurjo-Sáez M.

J Oncol Pharm Pract. 2018 Jan 1:1078155218775193. doi: 10.1177/1078155218775193. [Epub ahead of print]

PMID:
29792122
5.

Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.

González J, Quiroga M, Escudero-Vilaplana V, Collado-Borrell R, Herranz-Alonso A, Sanjurjo Sáez M.

Expert Opin Drug Saf. 2018 Jun;17(6):553-572. doi: 10.1080/14740338.2018.1477937. Epub 2018 May 28. Review.

PMID:
29781751
6.

Multidisciplinary strategy to reduce errors with the use of medical gases.

Amor-García MÁ, Ibáñez-García S, Díaz-Redondo A, Herranz Alonso A, Sanjurjo Sáez M.

Farm Hosp. 2018 May 1;42(3):103-107. doi: 10.7399/fh.10920.

PMID:
29730980
7.

Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.

Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, García Martín E, Mateos Mayo A, Sanjurjo Saez M.

J Dermatolog Treat. 2018 May 7:1-5. doi: 10.1080/09546634.2018.1466978. [Epub ahead of print]

PMID:
29676189
8.

[Failure mode and effects analysis to improve quality in clinical trials].

Mañes-Sevilla M, Marzal-Alfaro MB, Romero Jiménez R, Herranz-Alonso A, Sanchez Fresneda MN, Benedi Gonzalez J, Sanjurjo-Sáez M.

Rev Calid Asist. 2018 Jan - Feb;33(1):33-47. doi: 10.1016/j.cali.2017.12.001. Epub 2018 Feb 15. Spanish.

PMID:
29456173
9.

Pazopanib-Associated Transient Ischemic Attack.

Revuelta-Herrero JL, Escudero-Vilaplana V, Álvarez-Álvarez R, Sanjurjo-Sáez M.

Am J Ther. 2018 May/Jun;25(3):e393-e394. doi: 10.1097/MJT.0000000000000710. No abstract available.

PMID:
29424756
10.

Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.

Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M; GRUviC Study Group.

Expert Opin Drug Saf. 2018 Mar;17(3):235-241. doi: 10.1080/14740338.2018.1424829. Epub 2018 Jan 11.

PMID:
29325476
11.

Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.

Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M.

Ann Pharmacother. 2018 Jan;52(1):11-18. doi: 10.1177/1060028017728294. Epub 2017 Aug 24.

PMID:
28836468
12.

Eosinophilia secondary to lenalidomide therapy.

Escudero-Vilaplana V, Osorio-Prendes S, Collado-Borrell R, González-Arias E, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2018 Apr;43(2):273-275. doi: 10.1111/jcpt.12611. Epub 2017 Aug 17.

PMID:
28833364
13.

Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.

Arrabal-Durán P, Rodríguez-González CG, Chamorro-de-Vega E, Gijón-Vidaurreta P, Herranz-Alonso A, Sanjurjo-Sáez M.

Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12968. Epub 2017 Jul 19.

PMID:
28722790
14.

Clinical and Economic Impact of a Multisciplinary Intervention to Reduce Bleeding Risk in Patients With Acute Coronary Syndrome.

de Lorenzo-Pinto A, Herranz-Alonso A, Cuéllar-Basterrechea B, Bellón-Cano JM, Sanjurjo-Sáez M, Bueno H.

Rev Esp Cardiol (Engl Ed). 2017 Oct;70(10):825-831. doi: 10.1016/j.rec.2016.12.043. Epub 2017 Apr 12. English, Spanish.

PMID:
28411029
15.

Comparative study of preparation of hazardous drugs with different closed-system drug transfer devices by means of simulation with fluorescein.

González-Haba Peña E, Manrique Rodríguez S, Herranz Alonso AM, Pérez Castán P, Moreno Gálvez M, Iglesias Peinado I, Sanjurjo Saez M.

Farm Hosp. 2016 Nov 1;40(n06):496-503.

16.

Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.

Collado-Borrell R, Escudero-Vilaplana V, Romero-Jiménez R, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo-Sáez M.

J Cancer Res Clin Oncol. 2016 Nov;142(11):2319-30. doi: 10.1007/s00432-016-2190-8. Epub 2016 Jun 17. Review.

PMID:
27316629
17.

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration.

de Lorenzo-Pinto A, Giménez-Manzorro Á, Rodríguez-González CG, Ahumada-Jiménez A, Herranz-Alonso A, Marzal-Alfaro MB, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2016 Aug;41(4):444-446. doi: 10.1111/jcpt.12403. Epub 2016 May 9.

PMID:
27159430
18.

Safe intravenous administration in pediatrics: A 5-year Pediatric Intensive Care Unit experience with smart pumps.

Manrique-Rodríguez S, Sánchez-Galindo AC, Fernández-Llamazares CM, Calvo-Calvo MM, Carrillo-Álvarez Á, Sanjurjo-Sáez M.

Med Intensiva. 2016 Oct;40(7):411-21. doi: 10.1016/j.medin.2016.01.011. Epub 2016 Mar 26. English, Spanish.

19.

Smartphone applications for cancer patients; what we know about them?

Collado-Borrell R, Escudero-Vilaplana V, Ribed-Sánchez A, Ibáñez-García S, Herranz-Alonso A, Sanjurjo-Sáez M.

Farm Hosp. 2016 Jan 1;40(1):25-35. doi: 10.7399/fh.2016.40.1.8993.

20.

Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents.

Escudero-Vilaplana V, Ribed A, Romero-Jimenez RM, Herranz-Alonso A, Sanjurjo-Saez M.

Eur J Cancer Care (Engl). 2017 May;26(3). doi: 10.1111/ecc.12463. Epub 2016 Feb 12.

PMID:
26872286

Supplemental Content

Loading ...
Support Center